Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:01:41.261Z.
Calculation as of: 2026-10-06T18:01:41.261Z.
Quote observation: 2026-10-06T17:59:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 003104a745df447911be4c5a9e680832c7b19445192e606e8359fbce1df4db86
PE RATIO
N/A
Market Cap
$1.03M
PE Ratio
N/A
TTM Avg
173046.93
3Y Avg
281427.36
5Y Avg
281427.36
Market Cap
$862370.00
PE Ratio
N/A
TTM Avg
123162.46
3Y Avg
123162.46
5Y Avg
123162.46
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.06M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | N/A | 173046.93 | 281427.36 | 281427.36 |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.15M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.18M | N/A | 0.03 | 0.03 | 0.03 |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $868085.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $862370.00 | N/A | 123162.46 | 123162.46 | 123162.46 |
| Bone Biologics Corporation (BBLG)vs › | $859749.00 | N/A | 0.00 | 0.00 | 0.00 |
| Decoy Therapeutics Inc. (DCOY)vs › | $851149.00 | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
